Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
Pliant Therapeutics (Nasdaq: PLRX) will participate in the Piper Sandler 37th Annual Healthcare Conference, December 2–4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pliant Therapeutics (Nasdaq: PLRX) will participate in the Piper Sandler 37th Annual Healthcare Conference, December 2–4, 2025. A fireside chat featuring Bernard Coulie, M.D., Ph.D. (CEO), Keith Cummings, M.D. (CFO) and Éric Lefebvre, M.D. (CMO) is scheduled for Thursday, December 4, 2025 at 12:30 p.m. ET.
Interested parties can access a live webcast via the company’s Investor Relations Events & Presentation page. A replay will be archived on the Pliant website for 90 days after the event.
Details
News Market Reaction – PLRX
On Dec 1, the day this news came out, PLRX closed 4.97% below the previous close.
Data tracked by StockTitan Argus for the Dec 1 session.
Key Figures
- Conference dates
- December 2–4, 2025
- Piper Sandler 37th Annual Healthcare Conference
- Fireside chat time
- 12:30 p.m. Eastern Time
- Scheduled on Thursday, December 4, 2025
- Webcast replay window
- 90 days
- Replay available on company website after event
Historical Context
-
Interim Phase 1 PLN‑101095 data showed multiple responders and tolerability.
-
Announcement of participation and webcast access for Piper Sandler conference.
-
Q3 2025 results with lower expenses, reduced net loss and strong cash balance.
-
Q2 2025 results plus discontinuation of bexotegrast in IPF and restructuring.
-
BEACON‑IPF trial terminated after unfavorable safety and risk‑benefit profile.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
integrin-based therapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37th Annual Healthcare Conference to be held December 2 – 4, 2025.
Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, Keith Cummings, M.D., Chief Financial Officer and Éric Lefebvre, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 4, 2025, at 12:30 p.m. Eastern Time.
Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 90 days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.